U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07011706) titled 'ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis' on May 27.
Brief Summary: This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Atopic
Dermatitis
AD
Eczema
Intervention:
DRUG: ATI-045
ATI-045 group
DRUG: Placebo
Placebo group
Recruitment Status: RECRUITING
Sponsor: Aclaris Therapeutics, Inc.
Disclaimer: Curated by HT Syndication....